HRP20110768T1 - Pirazolopirimidinonski inhibitor kinaze - Google Patents
Pirazolopirimidinonski inhibitor kinaze Download PDFInfo
- Publication number
- HRP20110768T1 HRP20110768T1 HR20110768T HRP20110768T HRP20110768T1 HR P20110768 T1 HRP20110768 T1 HR P20110768T1 HR 20110768 T HR20110768 T HR 20110768T HR P20110768 T HRP20110768 T HR P20110768T HR P20110768 T1 HRP20110768 T1 HR P20110768T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- individual
- pharmaceutically acceptable
- active substance
- acceptable salt
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical compound N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 20
- 150000003839 salts Chemical class 0.000 claims 11
- 239000013543 active substance Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 241000283984 Rodentia Species 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 108091007914 CDKs Proteins 0.000 claims 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Spoj koji je (i) spoj formule (I),ili (ii) tautomer spoja pod (i). Patent sadrži još 16 patentnih zahtjeva.
Claims (17)
1. Spoj koji je (i) spoj formule (I),
[image]
ili (ii) tautomer spoja pod (i).
2. Farmaceutski prihvatljiva sol spoja prema zahtjevu 1, posebno klorovodična sol ili maleat spoja prema zahtjevu 1.
3. Prolijek spoja prema zahtjevu 1, ili farmaceutski prihvatljiva sol prema zahtjevu 2, pri čemu je prolijek (i) acetatni, formijatni ili benzoatni derivat fenolne hidroksilne skupine, ili (ii) N-aciloksialkil piridinij derivat.
4. Farmaceutska smjesa koja sadrži (i) djelatnu tvar koja se izabire između: spoja prema zahtjevu 1, farmaceutski prihvatljive soli prema zahtjevu 2, i prolijeka prema zahtjevu 3; i (ii) farmaceutski prihvatljivo punilo, pomoćnu tvar ili nosač.
5. Farmaceutska smjesa prema zahtjevu 4, koja je oblikovana (i) za oralnu primjenu ili (ii) za intravensku primjenu.
6. Farmaceutska smjesa prema zahtjevu 4 ili 5, koja sadrži terapijski učinkovitu količinu spomenute djelatne tvari.
7. Farmaceutska smjesa prema zahtjevu 6, oblikovana za primjenu pojedincu kojemu je potrebna, posebno kada se radi o primjeni pojedincu koji boluje od raka.
8. Farmaceutska smjesa prema zahtjevu 7, pri čemu je spomenuti pojedinac čovjek.
9. (a) Djelatna tvar izabrana između: spoja prema zahtjevu 1, farmaceutski prihvatljive soli prema zahtjevu 2, i prolijeka prema zahtjevu 3; ili (b) farmaceutska smjesa prema bilo kojem od zahtjeva 4 do 8, za uporabu u liječenju pojedinca koji boluje od raka, posebno kada je taj pojedinac sisavac izabran iz grupe koja obuhvaća: domaće životinje, glodavce i ljude, posebno kada je taj pojedinac čovjek.
10. Postupak ubijanja ili inhibicije proliferacije ili rasta tumorskih stanica, koji obuhvaća dovođenje u doticaj tumorske stanice sa spojem prema zahtjevu 1 ili njegovim oblikom soli, pri čemu se in vitro ta tumorska stanica izlaže spoju ili njegovoj soli, posebno kada je tumorska stanica maligna stanica pojedinca.
11. Postupak prema zahtjevu 10, pri čemu je pojedinac sisavac izabran iz grupe koja obuhvaća: domaće životinje, glodavce i ljude, posebno kada je taj pojedinac čovjek.
12. (a) Djelatna tvar izabrana između: spoja prema zahtjevu 1, farmaceutski prihvatljive soli prema zahtjevu 2, i prolijeka prema zahtjevu 3; ili (b) farmaceutska smjesa prema bilo kojem od zahtjeva 4 do 8, za uporabu u liječenju pojedinca koji boluje od poremećaja ili bolesti povezanih s aktivnošću jedne ili više ciklin ovisnih kinaza izabranih između: CDK1, CDK2, CDK4, CDK7 i CDK9, posebno kada je poremećaj ili bolest rak.
13. Djelatna tvar ili farmaceutska smjesa prema zahtjevu 12, pri čemu je poremećaj ili bolest povezana s aktivnošću CDK9.
14. Djelatna tvar ili farmaceutska smjesa prema zahtjevu 12 ili 13, pri čemu je pojedinac sisavac izabran iz grupe koja obuhvaća: domaće životinje, glodavce i ljude, posebno kada je taj pojedinac čovjek.
15. Uporaba djelatne tvari izabrane između: spoja prema zahtjevu 1, farmaceutski prihvatljive soli prema zahtjevu 2, i prolijeka prema zahtjevu 3; za pripremu lijeka za liječenje pojedinca koji boluje od raka.
16. Postupak sinteze spoja prema zahtjevu 1, ili po izboru njegove soli, koji obuhvaća korak reakcije spoja čija je struktura predstavljena formulom (II) sa spojem čija je struktura predstavljena formulom (III),
[image]
pri čemu se X bira između -O-alkil, -O-alkenil, -O-alkinil, -O-acil i halogena, posebno X je -OEt; i, po izboru, reakciju tako dobivenog spoja s kiselinom kako bi se dobila sol te kiseline.
17. Postupak sinteze farmaceutski prihvatljive soli prema 2, koji obuhvaća korak reakcije spoja prema zahtjevu 1 s kiselinom, posebno kada je kiselina klorovodična ili maleinska kiselina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93215507P | 2007-05-29 | 2007-05-29 | |
| EP07113226A EP2019101A1 (en) | 2007-07-26 | 2007-07-26 | Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor |
| PCT/EP2008/056569 WO2008145678A1 (en) | 2007-05-29 | 2008-05-28 | Pyrazolopyrimidinone kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110768T1 true HRP20110768T1 (hr) | 2011-11-30 |
Family
ID=38556321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110768T HRP20110768T1 (hr) | 2007-05-29 | 2011-10-24 | Pirazolopirimidinonski inhibitor kinaze |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8304418B2 (hr) |
| EP (2) | EP2019101A1 (hr) |
| JP (1) | JP2010528088A (hr) |
| KR (1) | KR20100040806A (hr) |
| CN (1) | CN101765600A (hr) |
| AR (1) | AR066737A1 (hr) |
| AT (1) | ATE522533T1 (hr) |
| AU (1) | AU2008257534A1 (hr) |
| CA (1) | CA2689090A1 (hr) |
| DK (1) | DK2170891T3 (hr) |
| EA (1) | EA200901536A1 (hr) |
| ES (1) | ES2370677T3 (hr) |
| HR (1) | HRP20110768T1 (hr) |
| IL (1) | IL202375A0 (hr) |
| MX (1) | MX2009012832A (hr) |
| SI (1) | SI2170891T1 (hr) |
| TW (1) | TW200906831A (hr) |
| WO (1) | WO2008145678A1 (hr) |
| ZA (1) | ZA200908943B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8586598B2 (en) * | 2009-04-29 | 2013-11-19 | Nerviano Medical Sciences S.R.L. | CDK inhibitor salts |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| WO2015172713A1 (zh) * | 2014-05-13 | 2015-11-19 | 广东东阳光药业有限公司 | 一种中间体的制备方法 |
| JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3916889A (en) * | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4710384A (en) * | 1986-07-28 | 1987-12-01 | Avner Rotman | Sustained release tablets made from microcapsules |
| EG18377A (en) * | 1986-09-19 | 1993-04-30 | Lilly Co Eli | Process for preparing glycopeptide antibiotics |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| PL174721B1 (pl) * | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6531477B1 (en) * | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| US6559152B2 (en) * | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| DE60035337T2 (de) | 2000-05-12 | 2008-02-28 | Gpc Biotech Ag | Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoider Tumorzellen, herbeiführen oder bewirken |
| IT1317975B1 (it) | 2000-06-16 | 2003-07-21 | Christian Pio Pedulla | Presa multipla volante. |
| WO2003063764A2 (en) * | 2001-07-10 | 2003-08-07 | Bristol-Myers Squibb Pharma Company | 6-SUBSTITUTED PYRAZOLO [3,4-d] PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| EP1832589A1 (en) * | 2001-10-15 | 2007-09-12 | GPC Biotech Inc. | Inhibitors of cyclin-dependent kinases,compositions and uses related thereto |
| SG173222A1 (en) * | 2003-04-07 | 2011-08-29 | Agennix Usa Inc | Aminoindeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases, useful for the treatment of alopecia, viral infections and hyperproliferative disorders, a pharmaceutical composition and uses related thereto |
| WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| EP1709051A1 (en) | 2003-12-23 | 2006-10-11 | GPC Biotech Inc. | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
-
2007
- 2007-07-26 EP EP07113226A patent/EP2019101A1/en not_active Withdrawn
-
2008
- 2008-05-28 AR ARP080102229A patent/AR066737A1/es unknown
- 2008-05-28 CN CN200880100285A patent/CN101765600A/zh active Pending
- 2008-05-28 EP EP08760162A patent/EP2170891B1/en not_active Not-in-force
- 2008-05-28 CA CA002689090A patent/CA2689090A1/en not_active Abandoned
- 2008-05-28 SI SI200830428T patent/SI2170891T1/sl unknown
- 2008-05-28 JP JP2010509817A patent/JP2010528088A/ja active Pending
- 2008-05-28 US US12/602,021 patent/US8304418B2/en not_active Expired - Fee Related
- 2008-05-28 DK DK08760162.1T patent/DK2170891T3/da active
- 2008-05-28 AT AT08760162T patent/ATE522533T1/de active
- 2008-05-28 EA EA200901536A patent/EA200901536A1/ru unknown
- 2008-05-28 WO PCT/EP2008/056569 patent/WO2008145678A1/en active Application Filing
- 2008-05-28 AU AU2008257534A patent/AU2008257534A1/en not_active Abandoned
- 2008-05-28 KR KR1020097027211A patent/KR20100040806A/ko not_active Application Discontinuation
- 2008-05-28 ES ES08760162T patent/ES2370677T3/es active Active
- 2008-05-28 MX MX2009012832A patent/MX2009012832A/es not_active Application Discontinuation
- 2008-05-29 TW TW097119933A patent/TW200906831A/zh unknown
-
2009
- 2009-11-26 IL IL202375A patent/IL202375A0/en unknown
- 2009-12-15 ZA ZA200908943A patent/ZA200908943B/xx unknown
-
2011
- 2011-10-24 HR HR20110768T patent/HRP20110768T1/hr unknown
-
2012
- 2012-10-09 US US13/647,572 patent/US20130035349A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2170891B1 (en) | 2011-08-31 |
| US8304418B2 (en) | 2012-11-06 |
| DK2170891T3 (da) | 2011-12-12 |
| AU2008257534A1 (en) | 2008-12-04 |
| ES2370677T3 (es) | 2011-12-21 |
| SI2170891T1 (sl) | 2011-12-30 |
| MX2009012832A (es) | 2010-05-17 |
| ZA200908943B (en) | 2010-08-25 |
| AR066737A1 (es) | 2009-09-09 |
| IL202375A0 (en) | 2010-06-30 |
| EA200901536A1 (ru) | 2010-06-30 |
| WO2008145678A1 (en) | 2008-12-04 |
| CA2689090A1 (en) | 2008-12-04 |
| JP2010528088A (ja) | 2010-08-19 |
| EP2170891A1 (en) | 2010-04-07 |
| TW200906831A (en) | 2009-02-16 |
| CN101765600A (zh) | 2010-06-30 |
| EP2019101A1 (en) | 2009-01-28 |
| US20130035349A1 (en) | 2013-02-07 |
| ATE522533T1 (de) | 2011-09-15 |
| KR20100040806A (ko) | 2010-04-21 |
| US20100160350A1 (en) | 2010-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015319831B2 (en) | Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof | |
| JP6509386B2 (ja) | ｍＴＯＲ経路関連疾患を治療するための化合物 | |
| DK2580206T3 (en) | PHARMACEUTICAL COMPOSITION, WHICH INCLUDES an amide derivative or a pharmaceutically acceptable salt thereof | |
| US11918562B2 (en) | Combination therapy using azabicyclo compound for cancer | |
| MX2010003927A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. | |
| SK363392A3 (en) | Stabilized pharmaceutical agent containing hgm-coa compound of inhibitor of reductase | |
| HRP20110768T1 (hr) | Pirazolopirimidinonski inhibitor kinaze | |
| CN1794986B (zh) | 治疗癌症的新药物 | |
| CN101484443B (zh) | 放射线治疗增强剂 | |
| US8580793B2 (en) | Use of kinase inhibitor for the treatment of thymoma | |
| TW202033191A (zh) | 新穎藥物組成物及其用途 | |
| JP7064094B2 (ja) | セルラタンジテルペンの医薬用途 | |
| EP3195867A1 (en) | Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin e2, method of production thereof and use thereof | |
| JP6931067B2 (ja) | Ｉｄｏの発現が関与する疾患の予防及び／又は治療剤 | |
| CN100377709C (zh) | 受体酪氨酸激酶抑制剂的制药用途及相关检测方法 | |
| KR20230019590A (ko) | 피롤로피리미딘아민 유도체를 유효성분으로 함유하는 항암 방사선 치료 민감제 | |
| WO2021025065A1 (ja) | アザ二環式化合物とポリアデノシン５'二リン酸リボースポリメラーゼ阻害剤を用いたがん併用療法 | |
| AU2016227883A1 (en) | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments | |
| SK171199A3 (en) | Method for producing medicaments containing hmg-coa-reductase inhibitors |